Oct 3
|
Bavarian Nordic (BVNRY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
Sep 27
|
UNICEF secures one million mpox vaccines for Africa
|
Sep 26
|
Bavarian Nordic Upgrades its Financial Guidance for 2024
|
Sep 26
|
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
|
Sep 25
|
Bavarian Nordic gains US contract for additional mpox vaccine
|
Sep 24
|
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines
|
Aug 27
|
Singapore approves mpox vaccine as it adds border infection checks
|
Aug 27
|
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore
|
Jul 26
|
Bavarian Nordic wins positive CHMP opinion to amend Imvanex approval
|
Jul 26
|
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
|
Jun 17
|
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
|
May 8
|
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
|
May 8
|
Bavarian Nordic Announces Interim Results for the First Three Months of 2024
|
Mar 21
|
Bavarian Nordic A/S – Notice Convening Annual General Meeting
|
Nov 30
|
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
|
Jun 27
|
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
|
Jun 23
|
Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve
|
Jun 20
|
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
|
Jun 16
|
Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate
|
Apr 25
|
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
|